Related references
Note: Only part of the references are listed.Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
Nicole E. Scharping et al.
NATURE IMMUNOLOGY (2021)
Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
Taigo Kato et al.
ONCOIMMUNOLOGY (2021)
Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFN gamma-Dependent Tumor Vessel Regression
Yutaka Kurebayashi et al.
CANCER RESEARCH (2021)
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
Nathan D. Mathewson et al.
CELL (2021)
Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models
Joseph R. Campbell et al.
CANCER RESEARCH (2021)
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models
Axel Hyrenius-Wittsten et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
Joseph H. Choe et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Zohreh Amoozgar et al.
NATURE COMMUNICATIONS (2021)
Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma
Justyna M. Przystal et al.
CANCERS (2021)
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Alexandra M. Miggelbrink et al.
CLINICAL CANCER RESEARCH (2021)
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn N. Krasner et al.
GYNECOLOGIC ONCOLOGY (2021)
TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
Karen O. Dixon et al.
NATURE (2021)
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
Yugang Guo et al.
NATURE IMMUNOLOGY (2021)
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Bruno L. Cadilha et al.
SCIENCE ADVANCES (2021)
Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity
Hisataka Kobayashi et al.
INTERNATIONAL IMMUNOLOGY (2021)
CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress
Sarah A. Holstein et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer
Jiefei Han et al.
CANCER IMMUNOLOGY RESEARCH (2020)
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers
Karolina I. Woroniecka et al.
CLINICAL CANCER RESEARCH (2020)
CAR T cells and checkpoint inhibition for the treatment of glioblastoma
Steven H. Shen et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours
Eric Song et al.
NATURE (2020)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami et al.
NATURE MEDICINE (2020)
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
Abhishek S. Kashyap et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
Joseph A. Flores-Toro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
Yaqing Zhang et al.
CANCER DISCOVERY (2020)
Blockade of β-Catenin-Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration
Lu Ji et al.
CANCER RESEARCH (2020)
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma
Jun-Xia Cao et al.
CYTOTHERAPY (2020)
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Jerry B. Harvey et al.
FRONTIERS IN IMMUNOLOGY (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
Annelisa M. Cornel et al.
CANCERS (2020)
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
Da-Ke Li et al.
ONCOLOGY LETTERS (2020)
Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways
Yi-Na Liu et al.
FRONTIERS IN IMMUNOLOGY (2020)
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
Jean-Pascal Machiels et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara et al.
LANCET ONCOLOGY (2020)
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
Megan M. Tu et al.
COMMUNICATIONS BIOLOGY (2020)
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1
Asaf Poran et al.
CELL REPORTS MEDICINE (2020)
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
Isabelle Solomon et al.
NATURE CANCER (2020)
The degree of conserved interferon gamma signaling guides response to immune checkpoint blockade therapy
Catherine Grasso et al.
CANCER RESEARCH (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
HIF Inhibitors: Status of Current Clinical Development
Jaleh Fallah et al.
CURRENT ONCOLOGY REPORTS (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma
Ying Liu et al.
JOURNAL OF IMMUNOLOGY (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Amy L. Shergold et al.
PHARMACOLOGICAL RESEARCH (2019)
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Shihong Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Neoantigen vaccine: an emerging tumor immunotherapy
Miao Peng et al.
MOLECULAR CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
OX40 (CD 134) and OX40 ligand, important immune checkpoints in cancer
Juan Deng et al.
ONCOTARGETS AND THERAPY (2019)
Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges
Muhammad Zaeem Noman et al.
CELLS (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
Zeyu Chen et al.
IMMUNITY (2019)
Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
Alvaro Teijeira et al.
CANCER IMMUNOLOGY RESEARCH (2019)
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma
Bryan D. Choi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Macrophages as regulators of tumour immunity and immunotherapy
David G. DeNardo et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
The Immune Revolution: A Case for Priming, Not Checkpoint
Robert H. Vonderheide
CANCER CELL (2018)
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Karolina Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
Ashley V. Menk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment
Elisa Peranzoni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Sujita Sukumaran et al.
CANCER DISCOVERY (2018)
High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma
Lei Li et al.
THORACIC CANCER (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability
Franck Raynaud et al.
PLOS GENETICS (2018)
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
David L. Bajor et al.
ONCOIMMUNOLOGY (2018)
Human monocytes and macrophages regulate immune tolerance via integrin alpha v beta 8-mediated TGF beta activation
Aoife Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
Xiaoguang Li et al.
GUT (2017)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression (vol 47, pg 323, 2017)
Yu Zhu et al.
IMMUNITY (2017)
Hypoxia inducible factor-1α regulates autophagy via the p27-E2F1 signaling pathway
Pan Wang et al.
MOLECULAR MEDICINE REPORTS (2017)
CCR8+FOXp3+ Treg cells as master drivers of immune regulation
Yiftah Barsheshet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
Takahiro Tsujikawa et al.
CELL REPORTS (2017)
Partial CD25 Antagonism Enables Dominance of Antigen-inducible CD25high FOXP3+ Regulatory T Cells As a Basis for a Regulatory T Cell-Based Adoptive Immunotherapy
Daniel S. Wilkinson et al.
FRONTIERS IN IMMUNOLOGY (2017)
Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer
Joseph Chao et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Asis Palazon et al.
CANCER CELL (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Zhihong Chen et al.
CANCER RESEARCH (2017)
Transient Treg depletion enhances therapeutic anti-cancer vaccination
Scott A. Fisher et al.
IMMUNITY INFLAMMATION AND DISEASE (2017)
The Microenvironmental Landscape of Brain Tumors
Daniela F. Quail et al.
CANCER CELL (2017)
CD73 regulates anti-inflammatory signaling between apoptotic cells and endotoxin-conditioned tissue macrophages
Patrick S. Murphy et al.
CELL DEATH AND DIFFERENTIATION (2017)
Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma
Alexander Scholz et al.
EMBO MOLECULAR MEDICINE (2016)
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2016)
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial
S. M. Keefe et al.
ANNALS OF ONCOLOGY (2016)
Treg stability: to be or not to be
Abigail E. Overacre et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections
Daniel T. Utzschneider et al.
IMMUNITY (2016)
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
Marco De Simone et al.
IMMUNITY (2016)
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
George Plitas et al.
IMMUNITY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
Ran He et al.
NATURE (2016)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im et al.
NATURE (2016)
CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles
Yew Ann Leong et al.
NATURE IMMUNOLOGY (2016)
The epigenetic landscape of T cell exhaustion
Debattama R. Sen et al.
SCIENCE (2016)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken et al.
SCIENCE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies
Robert L. Bowman et al.
CELL REPORTS (2016)
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2016)
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Tuoqi Wu et al.
SCIENCE IMMUNOLOGY (2016)
Hypoxia-inducible factors in T lymphocyte differentiation and function. A Review in the Theme: Cellular Responses to Hypoxia
Jin-Hui Tao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2015)
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
Gregory L. Beatty et al.
GASTROENTEROLOGY (2015)
Brain barriers: Crosstalk between complex tight junctions and adherens junctions
Silvia Tietz et al.
JOURNAL OF CELL BIOLOGY (2015)
Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway
Haiwei Wu et al.
MOLECULAR MEDICINE REPORTS (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
TCR-signaling events in cellular metabolism and specialization
Danielle A. Chisolm et al.
FRONTIERS IN IMMUNOLOGY (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Dass S. Vinay et al.
BMB REPORTS (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer
Belal Chaudhary et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel et al.
SCIENCE (2014)
Endogenous Antibodies for Tumor Detection
Barrie S. Rich et al.
SCIENTIFIC REPORTS (2014)
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
Ines Pires da Silva et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Randomized Phase 2 Study of Pegylated SN-38 (EZN-2208) or Irinotecan Plus Cetuximab in Patients With Advanced Colorectal Cancer
Christopher R. Garrett et al.
CANCER (2013)
Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells
Ilseyar Akhmetzyanova et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy
Amy E. Moran et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice
Jason S. Ellis et al.
IMMUNOLOGY (2013)
Transient Foxp3+ regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells
Stephen R. Mattarollo et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Madhusudhanan Sukumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Andrea Sottoriva et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Progressive Loss of Memory T Cell Potential and Commitment to Exhaustion during Chronic Viral Infection
Jill M. Angelosanto et al.
JOURNAL OF VIROLOGY (2012)
Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioning
Gregg L. Semenza
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri et al.
CANCER CELL (2011)
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
Sebastian F. M. Haeusler et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
4-1BB signaling beyond T cells
Dass S. Vinay et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2011)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
T-Cell Activation under Hypoxic Conditions Enhances IFN-gamma Secretion
Jessica Roman et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2010)
CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression
Dachuan Jin et al.
CANCER RESEARCH (2010)
Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
Katjana Klages et al.
CANCER RESEARCH (2010)
Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity
Rachel H. McMahan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Hyun-Tak Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Sharmila Patel et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial
Daniela Matei et al.
GYNECOLOGIC ONCOLOGY (2009)
The significance of OX40 and OX40L to T-cell biology and immune disease
Michael Croft et al.
IMMUNOLOGICAL REVIEWS (2009)
The Expression and Function of the NKRP1 Receptor Family in C57BL/6 Mice
Jonathan G. Aust et al.
JOURNAL OF IMMUNOLOGY (2009)
The Role of OX40-Mediated Co-stimulation in T-Cell Activation and Survival
William L. Redmond et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Perivascular Spaces and the Two Steps to Neuroinflammation
Trevor Owens et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2008)
Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Shawn D. Blackburn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
How regulatory T cells work
Dario A. A. Vignali et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) - A novel strategy for the treatment of melanoma and other malignancies
Steven J. O'Day et al.
CANCER (2007)
Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts
Masako Seki et al.
ARTHRITIS AND RHEUMATISM (2007)
CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation -mediated apoptosis of effector CD4+ T cells
Pushpa Pandiyan et al.
NATURE IMMUNOLOGY (2007)
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
Ana C. Anderson et al.
SCIENCE (2007)
Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases
V. Mourmouras et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells
Zoltan Wiener et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms
William C. Aird
CIRCULATION RESEARCH (2007)
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
Scott L. Carter et al.
NATURE GENETICS (2006)
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression
Cecilia Oderup et al.
IMMUNOLOGY (2006)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
PE Fecci et al.
CANCER RESEARCH (2006)
Cutting edge: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor
DB Rosen et al.
JOURNAL OF IMMUNOLOGY (2005)
Cutting edge: Lectin-like transcript 1 is a ligand for the CD161 receptor
H Aldemir et al.
JOURNAL OF IMMUNOLOGY (2005)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B
SP Mathur et al.
GYNECOLOGIC ONCOLOGY (2005)
Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors
M De Palma et al.
CANCER CELL (2005)
Decreased FOXP3 levels in multiple sclerosis patients
J Huan et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cells
L Fahlén et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis
A Balandina et al.
BLOOD (2005)
Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes
S Lindley et al.
DIABETES (2005)
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia
C Imai et al.
LEUKEMIA (2004)
GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations
S Ronchetti et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function
SJ Lee et al.
JOURNAL OF IMMUNOLOGY (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Signal 3 determines tolerance versus full activation of naive CD8 T cells: Dissociating proliferation and development of effector function
JM Curtsinger et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cutting edge: Molecular analysis of the negative regulatory function of lymphocyte activation gene-3
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2002)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self-tolerance
J Shimizu et al.
NATURE IMMUNOLOGY (2002)
CD4+CD25+ immunoregulatory T cells:: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
RS McHugh et al.
IMMUNITY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
M Skobe et al.
NATURE MEDICINE (2001)
X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy
RS Wildin et al.
NATURE GENETICS (2001)
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3
CL Bennett et al.
NATURE GENETICS (2001)